These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10881133)

  • 21. Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina.
    Sosa Estani S; Segura EL
    Mem Inst Oswaldo Cruz; 1999; 94 Suppl 1():363-5. PubMed ID: 10677756
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of the ELISA-F29 test as an early marker of therapeutic efficacy in adults with chronic Chagas disease.
    Fabbro D; Velazquez E; Bizai ML; Denner S; Olivera V; Arias E; Pravia C; Ruiz AM
    Rev Inst Med Trop Sao Paulo; 2013; 55(3):. PubMed ID: 23740013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
    Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
    Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of Chagas' disease].
    Apt W
    Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
    [No Abstract]   [Full Text] [Related]  

  • 25. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of a novel compound, (e)-1-(4'-bromo-4-biphenylyl)-1-(4-chlorophenyl)-3-dimethylaminoprop-1-ene against Trypanosoma cruzi in mice.
    Barrett PA; Beveridge E; Bull D; Caldwell IC; Islip PJ; Neal RA; Woods NC
    Experientia; 1982 Mar; 38(3):338-9. PubMed ID: 6804255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature.
    Molina I; Perin L; Aviles AS; de Abreu Vieira PM; da Silva Fonseca K; Cunha LM; Carneiro CM
    Acta Trop; 2020 Jan; 201():105218. PubMed ID: 31610148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perspectives in Chagas disease treatment.
    Oliveira GB; Avezum Á; Cordeiro Mattos AJ
    Glob Heart; 2015 Sep; 10(3):189-92. PubMed ID: 26407515
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease.
    Sosa Estani S; Segura EL; Ruiz AM; Velazquez E; Porcel BM; Yampotis C
    Am J Trop Med Hyg; 1998 Oct; 59(4):526-9. PubMed ID: 9790423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug discovery for chagas disease: A viewpoint.
    Kratz JM
    Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trypanocidal therapy among children infected by Trypanosoma cruzi. Serological and electrocardiographic changes over a mean twenty-five-years follow-up period.
    Suasnábar S; Olivera LV; Arias E; Bizai ML; Bottasso O; Arias E; Fabbro D
    Acta Trop; 2021 Oct; 222():106050. PubMed ID: 34302770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trypanocidal nitroarene treatment of experimental Trypanosoma cruzi infection does not prevent progression of chronic-phase heart lesions in rabbits.
    Teixeira AR; Cunha Neto E; Rizzo LV; Silva R
    J Infect Dis; 1990 Dec; 162(6):1420. PubMed ID: 2121842
    [No Abstract]   [Full Text] [Related]  

  • 33. [Recommendations for diagnosis, treatment and follow-up of the Trypanosoma cruzi: human immunodeficiency virus co-infection].
    Rev Soc Bras Med Trop; 2006; 39(4):392-415. PubMed ID: 17119760
    [No Abstract]   [Full Text] [Related]  

  • 34. [Chronic Chagas' disease: effects of treatment nn the levels of antibodies to crude and partially purified Trypanosoma cruzi antigens].
    Moretti E; Cervetta L; Basso B; Castro I; Santamarina N
    Bol Chil Parasitol; 1998; 53(1-2):3-9. PubMed ID: 9830716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study.
    Galvao LM; Nunes RM; Cançado JR; Brener Z; Krettli AU
    Trans R Soc Trop Med Hyg; 1993; 87(2):220-3. PubMed ID: 8337734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levels of anti-B13 antibodies over time in a cohort of chronic infected by Trypanosoma cruzi. Its relationship with specific treatment and clinical status.
    Olivera V; Bizai ML; Arias E; Suasnabar S; Bottasso O; Marcipar I; Fabbro D
    Acta Trop; 2021 Jun; 218():105908. PubMed ID: 33789152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chagas disease: hidden affliction and visible neglect.
    Weir E
    CMAJ; 2006 Apr; 174(8):1096. PubMed ID: 16606958
    [No Abstract]   [Full Text] [Related]  

  • 38. Current drug therapy and pharmaceutical challenges for Chagas disease.
    Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
    Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
    Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
    Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy of Chagas' disease: status and new developments.
    Cerecetto H; González M
    Curr Top Med Chem; 2002 Nov; 2(11):1187-213. PubMed ID: 12171581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.